Research On The Stability And Anticancer Activity Of Sulforaphene Preparation

Sulforaphene is a natural product with anti-cancer,anti-bacterial,and anti-oxidation activity,but it is not proprietary because of its easily degradable nature.In the traditional process,we use glucosinolate crude extract and myrosinase to produce sulforaphene.But the product has low purity and low yield.In this study,the stable substrate glucosinolate was purified by crystallization method,and the myrosinase was immobilized by resin.Then it results in economical,high purity and recovery of sulforaphene.In addition,in this study,the stability of sulforaphene was improved by preparation,and two dosage forms were designed with vials as,storage containers.The first one is a mixture of anhydrous excipients and sulforaphene dextrin powder.It has been found that the stability of sulforaphene is greatly improved by this way.The vitro activity experiments have also confirmed that it will not reduce the anti-cancer efficacy of sulforaphene.The other one is an inclusion compound formulation of hydroxypropyl-?-cyclodextrin and sulforaphene.The inclusion conditions were optimized in.this study and we use three characterization methods including Fourier infrared spectroscopy,Differential scanning calorimetry,and Scanning electron microscopy to confirm the formation of inclusion complexe.In vitro stability experiments also showed that the inclusion complexe can effectively improve the stability of sulforaphene.In vitro release experiments simulated the drug release of the inclusion complexes in vivo,demonstrating the sustained release effect of the inclusion complexes.The cell experiment also proved that the anticancer drug efficacy of the inclusion compound was broad spectrum and concentration dependence.Then the acute toxicity experiment was used to select the intraperitoneal injection method for in vivo activity experiments.It was found that the inclusion compound can not only increase the stability of sulforaphene,but also has less toxicity and better anticancer activity compared with the free drug.